行情

RGEN

RGEN

雷普里根
NASDAQ

实时行情|Nasdaq Last Sale

147.81
-4.96
-3.25%
盘后: 147.81 0 0.00% 16:06 08/10 EDT
开盘
152.56
昨收
152.77
最高
153.35
最低
147.58
成交量
47.26万
成交额
--
52周最高
159.97
52周最低
72.32
市值
77.60亿
市盈率(TTM)
253.84
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RGEN价格均价为159.43,最高价位170.00,最低价为140.00。

EPS

RGEN 新闻

更多
Repligen Reports Record Quarter, Increases 2020 Guidance
The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.
Motley Fool · 08/03 18:33
Did Hedge Funds Drop The Ball On Repligen Corporation (RGEN) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 08/03 17:10
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks · 07/31 13:15
Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/31 04:53
Repligen EPS beats by $0.14, beats on revenue
Repligen (NASDAQ:RGEN): Q2 Non-GAAP EPS of $0.42; GAAP EPS of $0.30 beats by $0.14. Revenue of $87.46M (+23.7% Y/Y) beats by $9.07M. Organic Revenue growth
seekingalpha · 07/30 16:33
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Repligen shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY20 EPS and sales guidance above analyst estimates.
Benzinga · 07/30 11:51
Repligen Raises FY20 Adj. EPS From $1.09-$1.14 To $1.24-$1.29 vs $1.13 Est., Raises FY20 Sales Guidance From $309M-$319M To $332M-$340M vs $317.04M Est.
Benzinga · 07/30 11:39

所属板块

医疗设备、用品及经销
-0.95%
医疗设备和用品
-0.98%

热门股票

代码
价格
涨跌幅

RGEN 简况

Repligen Corporation是一家生物加工公司。该公司专注于开发、生产和销售在生产生物药品(生物加工)过程中使用的产品业务。该公司是天然和重组形式的蛋白A的制造商,蛋白A是用于在生物制造过程分离和纯化单克隆抗体的一种关键生物试剂。该公司还提供几种生长因子产品、Alternating Tangential Flow (ATF) System产品以及用于在生物生产过程中提高细胞培养生产力的细胞过滤产品。该公司开发了一系列用于临床规模生产的OPUS色谱柱。该公司根据长期供应协议向生命科学公司生产和销售蛋白A和生长因子以及销售色谱柱及培养基和质量检测试剂盒。
展开

微牛提供Repligen Corporation(NASDAQ-RGEN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RGEN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RGEN股票基本功能。